AUTHOR=Caers Jo , Duray Elodie , Vrancken Louise , Marcion Guillaume , Bocuzzi Valentina , De Veirman Kim , Krasniqi Ahmet , Lejeune Margaux , Withofs Nadia , Devoogdt Nick , Dumoulin Mireille , Karlström Amelie Eriksson , D’Huyvetter Matthias 

TITLE=Radiotheranostic Agents in Hematological Malignancies

JOURNAL=Frontiers in Immunology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.911080

DOI=10.3389/fimmu.2022.911080

ISSN=1664-3224

ABSTRACT=Radioimmunotherapy (RIT) is cancer treatment that combines radiation therapy with tumor directed monoclonal antibodies (Abs). Although RIT has been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a broad clinical application. In recent years, researchers developed theranostic agents based on Ab fragments or small Ab mimetics such as peptides, affibodies or single-chain Abs with improved tumor-targeting capacities. Theranostics combines diagnostic and therapeutic capabilities into a single pharmaceutical agent and this dual application can be easily achieved after conjugation to radionuclides. The past decade has seen a growing trend to increased specificity, fastened pharmacokinetics and personalized medicine. In this review we discuss the different strategies that have been introduced for the non-invasive detection and treatment of hematological malignancies by radiopharmaceuticals. We also discuss future applications of these radiotheranostic agents.